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Research
Clinical characteristics, multiorgan dysfunction and
outcomes of patients with COVID-19: a prospective case
series
Kimia Honarmand MD MSc, Kyle Fiorini MD, Debarati Chakraborty MD, Daniel Gillett MD,
Karishma Desai MD, Claudio Martin MD MSc, Karen J. Bosma MD, Marat Slessarev MD MSc,
Ian M. Ball MD MSc, Tina Mele MD PhD, Danielle LeBlanc MSc, Sameer Elsayed MD MSc,
Alejandro Lazo-Langner MD MSc, Mike J. Nicholson MD, Robert Arntfield MD, John Basmaji MD

Abstract
Background: Characterizing the multiorgan manifestations and outcomes of patients hospitalized with COVID-19 will inform
resource requirements to address the long-term burden of this disease. We conducted a descriptive analysis using prospectively
collected data to describe the clinical characteristics and spectrum of organ dysfunction, and in-hospital and longer-term clinical outcomes of patients hospitalized with COVID-19 during the first wave of the pandemic at a Canadian centre.
Methods: We conducted a prospective case series involving adult patients (aged ≥ 18 yr) with COVID-19 admitted to 1 of 2 hospitals
in London, Ontario, from Mar. 17 to June 18, 2020, during the first wave of the pandemic. We recorded patients’ baseline characteristics, physiologic parameters, measures of organ function and therapies administered during hospitalization among patients in the
intensive care unit (ICU) and in non-ICU settings, and compared the characteristics of hospital survivors and nonsurvivors. Finally,
we recorded follow-up thoracic computed tomography (CT) and echocardiographic findings after hospital discharge.
Results: We enrolled 100 consecutive patients (47 women) hospitalized with COVID-19, including 32 patients who received ICU
care and 68 who received treatment in non-ICU settings. Respiratory sequelae were common: 23.0% received high-flow oxygen by
nasal cannula, 9.0% received noninvasive ventilation, 24.0% received invasive mechanical ventilation and 2.0% received venovenous extracorporeal membrane oxygenation. Overall, 9.0% of patients had cerebrovascular events (3.0% ischemic stroke, 6.0%
intracranial hemorrhage), and 6.0% had pulmonary embolism. After discharge, 11 of 19 patients had persistent abnormalities on CT
thorax, and 6 of 15 had persistent cardiac dysfunction on echocardiography.
Interpretation: This study provides further evidence that COVID-19 is a multisystem disease involving neurologic, cardiac and
thrombotic dysfunction, without evidence of hepatic dysfunction. Patients have persistent organ dysfunction after hospital discharge,
underscoring the need for research on long-term outcomes of COVID-19 survivors.

T

he typical clinical spectrum of COVID-19, the illness caused by SARS-CoV-2, ranges from mild
respiratory symptoms to multiorgan failure and
death.1,2 Emerging evidence has shown that COVID-19 is
associated with a range of pulmonary and extrapulmonary
organ involvement.3 Although early Canadian data shed light on
the outcomes and mortality rate, studies on the morbidity of
hospitalized patients have been sparse and often based on retrospectively collected data,4–6 and many have excluded patients
hospitalized outside the intensive care unit (ICU).5–7
To characterize the clinical course, multiorgan involvement and outcomes of COVID-19, prospectively collected
data are required. Such data may potentially inform Canadian
health care priorities as they relate to both the long-term
burden of COVID-19 and future pandemics. We conducted
a descriptive analysis using prospectively collected data to
describe the clinical characteristics and spectrum of organ
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dysfunction, and in-hospital and longer-term clinical outcomes of hospitalized patients with COVID-19 during the
first wave of the pandemic at a Canadian centre.
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Methods
Study design and setting

This prospective case series was conducted at 2 sites in London Health Sciences Centre, a 1116-bed academic, tertiary
care centre in London, Ontario, that comprises 2 hospitals:
Victoria Hospital and University Hospital. We report this
study in compliance with Strengthening the Reporting of
Observational Studies in Epidemiology (STROBE) guidelines
for reporting observational studies.8

Patient recruitment

We consecutively enrolled all adult patients admitted to hospital with a diagnosis of COVID-19 from Mar. 17 to June 18,
2020. Inclusion criteria included symptoms consistent with
COVID-19,1 age 18 years or older and a diagnosis of COVID19 confirmed by a positive nasopharyngeal or tracheal aspirate
polymerase chain reaction assay, either 7 days before hospital
admission (not including the day of hospital admission) or at
the time of the index hospitalization. We excluded patients
who declined to participate in the study.

Data collection

Several study authors (D.C., K.D., K.F., D.G., K.H. and J.B.)
screened all hospital admissions on a daily basis, enrolled eligible patients, and collected data prospectively using a pilottested case report form on the Research Electronic Data Capture (REDCap) platform, hosted by the Lawson Health
Research Institute. We employed branching logic and numerical validations in the REDCap case report form to enhance
data accuracy. One of the principal investigators (J.B. or K.H.)
reviewed all data collected daily to ensure accuracy and
completeness.
We recorded patients’ baseline demographic characteristics, physiologic parameters, investigations (including incidence and findings of computed tomography [CT], echocardiography and lung ultrasonography studies), therapies
administered throughout hospitalization in non-ICU and
ICU settings, and overall outcome (i.e., in-hospital death v.
discharge from hospital and discharge destination). Finally,
we recorded any echocardiography and thoracic CT scans
performed after hospital discharge for clinical indications up
until Dec. 31, 2020.
Echocardiography was conducted by an echocardiography technologist and the data were extracted by one of the
study authors (J.B.), who is an intensive care physician with
advanced training in point-of-care ultrasonography. Lung
ultrasound images were acquired and reported by emergency
physicians and critical care physicians. Data extraction was
done by a study author (J.B.). Computed tomography
reports were dictated by a radiologist. Data from the final
radiology report were extracted by one of the study investigators. We collected data from patients and their clinical
teams, paper charts, electronic medical records and the Critical Care Information System database. Appendix 1 (available at www.cmajopen.ca/content/10/3/E675/suppl/DC1)
provides a description of all data elements and sources.
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To ensure that our coding of the reports was relevant and
comprehensive, we used the expertise of the study team. The
study team consists of experts in these areas, including a respirologist (M.J.N.) and 2 intensive care physicians with
advanced training and expertise in point-of-care lung ultrasonography and echocardiography (J.B. and R.A.), one of whom
(R.A.) is an internationally recognized expert in advanced
point-of-care echocardiography. This expertise facilitated the
coding of relevant CT chest and echocardiographic data to
ensure that we recorded relevant information in a consistent
and accurate way, especially since we aimed to use the data to
delineate derangements in cardiac physiology as a result of
COVID-19.

Statistical analysis

We used descriptive statistics (means and standard deviations,
medians and interquartile ranges [IQRs], and proportions and
percentages, as appropriate) to summarize patients’ baseline
characteristics, physiologic parameters, therapies and
outcomes.
We applied the Wilcoxon rank-sum test for non
normally distributed continuous variables and the χ2 statistic for categorical variables, as appropriate, to compare
characteristics of hospital survivors with those of nonsurvivors. We also compared lung ultrasound findings of
patients who were not mechanically ventilated with the
findings of those who were mechanically ventilated,
expressed as an odds ratio with 95% confidence interval. In
addition, we compared the characteristics of patients who
were admitted to and remained in a non-ICU location with
characteristics of patients who were initially admitted to a
non-ICU location but were subsequently transferred to
ICU because of clinical deterioration.
We selected variables on the basis of prior retrospective
data showing an association between the variable and outcomes of interest.1,9 They included age, vital signs at emergency department triage, and laboratory data obtained on
admission, such as blood pH, white blood cell count, hemoglobin, platelets, lymphocyte count, lactate, ferritin, lactate
dehydrogenase, C-reactive protein and troponin levels. All
statistical tests are 2-sided, with the threshold of statistical significance set at a p value of less than 0.05. We performed all
data analyses using SPSS version 25.0 (IBM).

Ethics approval

Western University’s Research Ethics Board approved the
conduct of this study (study no. 115732; Apr. 1, 2020).

Results
From Mar. 17 to June 18, 2020, 101 patients were admitted to
1 of the participating hospitals with a positive SARS-CoV-2
test. Of those, 1 patient declined to participate in the study.
We included 100 patients (32 ICU and 68 non-ICU patients).
Figure 1 provides an overview of the recruitment procedures
and patients’ clinical disposition in hospital. Table 1 presents
patients’ baseline characteristics.

Research

Total patients hospitalized with COVID-19
N = 101
Patients excluded
• Did not consent n = 1

Eligible patients n = 100

Patients initially admitted to
ICU n = 20

Patients initially admitted to
non-ICU location n = 80

Patients transferred to ICU from a
non-ICU location
n = 12

Patients admitted to ICU n = 32

Remaining patients admitted to non-ICU
location n = 68

Patients survived to hospital discharge n = 18
• Discharged home n = 12
• Discharged to rehabilitation centre n = 4
• Transferred to acute care facility n = 2

Patients survived to hospital discharge n = 48
• Discharged home n = 35
• Discharged to rehabilitation centre n = 8
• Discharged to long-term care n = 5

Follow-up echocardiography and CT of chest
(until Dec. 31, 2020)
• Patients with CT chest scans n = 19
• Patients with echocardiograms n = 15

Figure 1: Overview of patient enrolment and disposition. Note: CT = computed tomography, ICU = intensive care unit.

Clinical presentation

Table 2 presents patients’ clinical characteristics at the time
of hospital admission. Symptoms reported by more than 50%
of patients at the time of hospitalization for COVID-19 were
cough, dyspnea, fever and fatigue. At the time of assessment
in the emergency department, 44.2% (42/95) of patients presented with a respiratory rate greater than 24 breaths/min,
and 35.4% (35/99) received supplemental oxygen therapy in
the emergency department to maintain oxygen saturation
levels above 92%.
Twenty patients were admitted to the ICU, and 80
patients were admitted to the ward. Among the 80 patients
initially admitted to the ward, 12 were eventually transferred

to the ICU after a median hospital stay of 0.5 (IQR 0–2) days.
Ultimately, 32 patients were admitted to the ICU.

Complications and management by organ system
Respiratory complications and therapies

Table 3 shows the respiratory complications and therapies
received during hospitalization. Among all 100 patients, 79
(79.0%) received supplemental oxygen therapy, including highflow nasal cannula (23/100), noninvasive ventilation (9/100),
invasive mechanical ventilation (24/100) and venovenous extracorporeal membrane oxygenation (2/100). Prone positioning
included awake self-proning in non-ICU patients (4/68
CMAJ OPEN, 10(3)
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Table 1: Baseline characteristics of patients admitted to hospital with COVID-19
No. (%)*
Characteristic

All patients
n = 100

Non-ICU patients
n = 68

ICU patients
n = 32

Demographic characteristics
Age, yr, median (IQR)

74 (56–83)

76 (60–85)

63 (55–74)

Sex, male

53 (53.0)

34 (50.0)

19 (59.4)

Body mass index, mean ± SD

n = 84
29.2 ± 8.2

n = 56
28.1 ± 7.9

n = 28
31.4 ± 8.5

Home

66 (66.0)

41 (60.3)

25 (78.1)

Long-term care facility

28 (28.0)

24 (35.3)

4 (12.5)

Preadmission location

Retirement home

1 (1.0)

1 (1.5)

0

Other

5 (5.0)

2 (2.9)

3 (9.4)

Chronic cardiac disease

24 (24)

17 (25.0)

7 (21.9)

Chronic pulmonary disease

17 (17)

14 (20.6)

3 (9.4)

Asthma

15 (15.0)

10 (14.7)

5 (15.6)

Chronic kidney disease

15 (15.0)

10 (14.7)

5 (15.6)

Liver disease

4 (4.0)

2 (2.9)

2 (6.3)

Chronic neurologic disorder

6 (6.0)

5 (7.4)

1 (3.1)

Cancer (active only)

9 (9.0)

7 (10.3)

2 (6.3)

Comorbidities

History of cancer (in remission)

8 (8.0)

7 (10.3)

1 (3.1)

Obesity

11 (11.0)

7 (10.3)

4 (12.5)

Diabetes

30 (30.0)

19 (27.9)

11 (34.4)

Dementia (any etiology)

16 (16.0)

15 (22.1)

1 (3.1)

7 (7.0)

5 (7.4)

2 (6.3)

Other comorbidities
Habits
Current smoker

9 (9.0)

7 (10.3)

2 (6.3)

28 (28.0)

22 (32.4)

6 (18.8)

Alcohol use (> 14 drinks per week)

4 (4.0)

4 (5.9)

0

Illicit drug use

1 (1.0)

1 (1.5)

0

Contact with confirmed case of SARS-CoV-2 infection

30 (30.0)

23 (33.8)

7 (21.9)

Contact with suspected case of SARS-CoV-2 infection

9 (9.0)

5 (7.4)

4 (12.5)

Travel outside Canada

9 (9.0)

6 (8.8)

3 (9.4)

Travel within Canada

1 (1.0)

0

1 (3.1)

Ex-smoker

Exposure history

Note: ICU = intensive care unit, IQR = interquartile range, SD = standard deviation.
*Unless stated otherwise.

patients) and standard proning of ventilated patients in the
ICU (13/30). Most ICU patients (24/32) received invasive
mechanical ventilation, with a median duration of 14 (IQR
10–22) days.
Twenty-six patients underwent CT of the thorax. The
most common findings were bilateral diffuse ground-glass
opacities, bilateral consolidations and new fibrosis or bronchiectasis (Table 3). Lung ultrasonography was performed on 30
E678
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patients. The most common abnormalities included thickened, irregular pleural line consistent with an inflammatory
process, bilateral alveolar-interstitial syndrome (B-lines) and
pulmonary consolidation (Table 3). Consolidation on lung
ultrasonography was more likely to be identified among
patients receiving mechanical ventilation than among those
not receiving mechanical ventilation (75% v. 33%, odds ratio
6.0, 95% confidence interval 1.17–30.73).

Research
Table 2: Clinical characteristics at the time of presentation to hospital
No. (%)*
All patients
n = 100

Characteristic

Non-ICU patients
n = 68

ICU patients
n = 32

Presenting symptom for > 20% of patients
Cough

71 (71.0)

50 (73.5)

21 (65.6)

Fever

62 (62.0)

37 (54.4)

25 (78.1)

Dyspnea

63 (63.0)

40 (58.8)

23 (71.9)

Fatigue

51 (51.0)

35 (51.5)

16 (50.0)

Diarrhea

32 (32.0)

23 (33.8)

9 (28.1)

Myalgia

25 (25.0)

13 (19.1)

12 (37.5)

Headache

23 (23.0)

13 (19.1)

10 (31.3)

Temperature > 38°C

36/98 (36.7)

19/67 (28.4)

17/31 (54.8)

Heart rate > 100 beats/min

31/96 (32.3)

18/66 (27.3)

13/30 (43.3)

3/98 (3.1)

2/67 (3.0)

1/30 (3.3)

Vital signs at hospital presentation

Systolic blood pressure < 90 mm Hg
Respiratory rate > 24 breaths/min

42/95 (44.2)

23/67 (34.3)

19/28 (67.9)

Oxygen saturation < 92%

20/98 (20.4)

8/67 (11.9)

12/31 (38.7)

Supplemental oxygen therapy at clinical presentation

35/99 (35.4)

18/67 (26.9)

17/32 (53.1)

10.6 ± 13.2

11.0 ± 15.4

10.0 ± 6.1

Laboratory results at hospital presentation, mean ± SD
Leukocyte count, x109/L
Lymphocyte count, x10 /L
9

Creatinine, µmol/L
LDH, U/L
Ferritin, µg/L
µg/L

4.2 ± 15.5

1.3 ± 1.3

106.9 ± 62.6

118.5 ± 110.8

416.3 ± 253.0

367.4 ± 177.5

563.0 ± 391.1

1702.6 ± 2154.4

1772.1 ± 2372.3

1424.4 ± 998.2

97.6 ± 83.5

87.9 ± 75.8

126.8 ± 101.9

1198.9 ± 1311.5

956.0 ± 789.4

1603.7 ± 2093.1

31.8 ± 42.1

36.3 ± 46.8

18.1 ± 17.5

CRP, mg/L
d-dimer,

3.3 ± 12.9
110.5 ± 80.1

Troponin, ng/L
Fibrinogen, g/L

7.5 ± 0.5

7.4 ± 0.7

–†

pH on blood gas

7.4 ± 0.1

7.4 ± 0.1

7.4 ± 0.1

Note: CRP = C-reactive protein, ICU = intensive care unit, LDH = lactate dehydrogenase, SD = standard deviation.
*Unless stated otherwise.
†One data point only.

Neurologic complications

Table 4 summarizes the short-term neurologic complications
among 26 (10 non-ICU, 16 ICU) patients who underwent
head CT during hospitalization. Three of 26 patients had an
ischemic stroke, and 6 of 26 patients had intracerebral hemorrhage. The 3 patients who had an ischemic stroke did not
have a history of previous ischemic stroke.

Thrombotic complications and therapies

Thrombotic complications and therapies are shown in
Table 4. Of the 13 (4 non-ICU, 9 ICU) patients who
underwent Doppler ultrasonography, 2 ICU patients had
deep venous thrombosis. Twenty-six (12 non-ICU and 14
ICU) patients underwent CT pulmonary angiography. Of
these, 6 had pulmonary embolism (3 of 68 non-ICU
patients and 3 of 32 ICU patients). Eleven (11.0%) patients

received therapeutic anticoagulation during their hospitalization: 3 empirically for suspected COVID-19-associated
hypercoagulable state, 7 for confirmed venous thrombo
embolic disease and 1 for venovenous extracorporeal membrane oxygenation circuit.

Cardiac and hemodynamic complications and therapies

Among 32 ICU patients, 24 (75.0%) received vasopressor therapy for a median of 9 (IQR 3.75–11.75) days. Four patients
received hydrocortisone for refractory shock (Table 4).
Twenty-nine patients underwent echocardiography during their hospital stay (including both point-of-care and
diagnostic). Overall, 4 (13.8%) patients had new left ventricular (LV) dysfunction and 9 (31.0%) patients had new right
ventricular (RV) dysfunction (defined as either new systolic
failure or pulmonary hypertension).
CMAJ OPEN, 10(3)
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Table 3: Pulmonary complications and management among patients hospitalized with COVID-19
No. (%)*
All patients
n = 100

Non-ICU patients
n = 68

ICU patients
n = 32

PF ratio < 150 mm Hg

NA

NA

27/32 (84.4)

Duration of PF ratio < 150 mm Hg, d, median (IQR)

NA

NA

8 (4–15)

Complications and management
Clinical parameters

CT chest findings†
Localized ground-glass opacities

4/26 (15.4)

3/12 (25)

1/14 (7.1)

Diffuse ground-glass opacities

14/26 (53.8)

5/12 (41.7)

9/14 (64.3)

2/26 (7.7)

1/12 (8.3)

1/14 (7.1)

Unilateral consolidation or infiltration
Bilateral consolidation or infiltration

14/26 (53.8)

7/12 (58.3)

7/14 (50.0)

Unilateral pleural effusion

2/26 (7.7)

0/12 (0)

2/14 (14.3)

Bilateral pleural effusion

3/26 (11.5)

2/12 (16.7)

1/14 (7.1)

Emphysematous changes or bronchiectasis

4/26 (15.4)

2/12 (16.7)

2/14 (14.3)

Scarring or fibrosis

4/26 (15.4)

0/12 (0)

4/14 (28.6)

2/26 (7.7)

1/12 (8.3)

1/14 (7.1)

Irregular pleural line

26/30 (86.7)

5/7 (71.4)

21/23 (91.3)

Alveolar-interstitial syndrome (B-lines)

28/30 (93.3)

5/7 (71.4)

23/23 (100)

12/30 (40)

0/6 (0)

12/24 (50.0)

Organizing pneumonia pattern
Lung ultrasonography findings‡

Consolidation
Unilateral

2/12 (16.7)

0/6 (0)

2/12 (16.7)

Bilateral

10/12 (83.3)

0/6 (0)

10/12 (83.3)

2/30 (6.7)

0/7 (0)

2/23 (8.7)

Received oxygen therapy

79/100 (79.0)

47/68 (69.1)

32/32 (100.0)

High-flow nasal cannula

23/100 (23.0)

5/68 (7.4)

18/32 (56.3)

Moderate–large pleural effusion
Respiratory therapies

Noninvasive ventilation
Invasive ventilation

9/100 (9.0)

1/68 (1.5)

8/32 (25.0)

24/100 (24.0)

0/68 (0)

24/32 (75.0)

NA

NA

n = 27
14 (10–22)

17/98 (17.3)

4/68 (5.9)

13/30 (43.3)

Duration of invasive and noninvasive ventilation in
ICU, d, median (IQR)
Prone positioning
Neuromuscular blocking agents
Steroids for respiratory failure

NA

NA

18/32 (56.3)

8/100 (8.0)

4/68 (5.9)

4/32 (12.5)

NA

NA

2/32 (6.3)

VV-ECMO

Note: CT = computed tomography, ICU = intensive care unit, IQR = interquartile range, NA = not applicable, PF ratio = Pao2/Fio2 ratio, VV-ECMO = venovenous
extracorporeal membrane oxygenation.
*Unless stated otherwise.
†Results reflect CT done during hospitalization.
‡Results reflect lung ultrasonography done during hospitalization.

Hepatic complications

Alanine aminotransferase (ALT) levels were used as a surrogate
marker for hepatic dysfunction in patients with COVID-19.
The median of the highest ALT level across all study participants during hospital admission was 31 (IQR 22 to 82) U/L.

Renal complications and therapies

In 27 (27.0%) patients (non-ICU: 11/68 [16.2%]; ICU: 16/32
[50.0%]), an acute kidney injury developed. Among ICU
E680
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patients, 5 received continuous renal replacement therapy for a
median of 4 (IQR 2.0–6.5) days (Table 4). At the time of hospital discharge, 3 of 66 patients (4.5%) had persistent renal injury.

Secondary infections

Fifteen of 100 (15.0%) patients had an initially negative SARSCoV-2 real-time polymerase chain reaction test, which was subsequently positive on repeat testing. In 13 patients, concomitant
respiratory infections developed: 12 (12.0%) patients had bacterial

Research
Table 4: Extrapulmonary complications among patients hospitalized with COVID-19
No. (%)*
All patients
n = 100

Non-ICU patients
n = 68

ICU patients
n = 32

Ischemic stroke

3/26 (11.5)

1/10 (10.0)

2/16 (12.5)

Intracranial hemorrhage

6/26 (23.1)

0

6/16 (37.5)

Complications and management
Neurologic complications

Thrombotic complications and therapies
Deep venous thrombosis on ultrasonography

2/13 (15.4)

0

2/9 (22.2)

Pulmonary embolism on CTPA

6/26 (23.1)

3/12 (25.0)

3/14 (21.4)

11/100 (11.0)

3/68 (4.4)

8/32 (25.0)

3/100 (3.0)

0

3/32 (9.4)

Started for confirmed venous thromboembolism

7/100 (7.0)

3/68 (4.4)

4/32 (12.5)

Started for VV-ECMO circuit

1/100 (1.0)

0

1/32 (3.1)

Received vasopressors or inotropes

NA

NA

24/32 (75.0)

Duration of vasopressors or inotropes, d, median (IQR)

NA

NA

n = 24
9 (3.75–11.75)

4/100 (4.0)

0

4/32 (12.5)

Received therapeutic anticoagulation
Started for presumed hypercoagulable state from
COVID-19

Cardiac and hemodynamic complications and therapies

Corticosteroids for hemodynamic shock
Echocardiography findings†
Depressed LVEF (30%–50%)

2/29 (6.9)

0/5 (0)

2/24 (8.3)

Severely depressed LVEF (< 30%)

2/29 (6.9)

1/5 (20.0)

1/24 (4.2)

Reduced RV systolic function

5/29 (17.2)

1/5 (20.0)

3/24 (12.5)

Pulmonary hypertension

9/29 (31.0)

2/5 (40.0)

7/24 (29.2)

Pericardial effusion

1/29 (3.4)

0/5 (0)

1/24 (4.2)

27/100 (27.0)

11/68 (16.2)

16/32 (50.0)

Received CRRT

NA

NA

5/32 (15.6)

Duration of CRRT, median (IQR)

NA

NA

4 (2.0–6.5)

Stage I

16/100 (16.0)

9/68 (13.2)

7/32 (21.9)

Stage II

5/100 (5.0)

0

5/32 (15.6)

Stage III

6/100 (6.0)

2/68 (2.9)

4/32 (12.5)

13/100 (13.0)

0

13/32 (40.6)

Positive blood culture

8/100 (8.0)

2/68 (2.9)

6/32 (18.8)

Positive urine culture

15/100 (15.0)

4/68 (5.9)

11/32 (34.4)

Clostridioides difficile

1/100 (1.0)

1/68 (1.5)

0

Renal complications and therapies
Acute kidney injury‡

Highest AKIN stage

Secondary infections
Positive respiratory culture (bacterial or fungal)

Note: AKIN = Acute Kidney Injury Network, CTPA = computed tomography pulmonary angiography, CRRT = continuous renal replacement therapy, ICU = intensive care
unit, IQR = interquartile range, LVEF = left ventricular ejection fraction, NA = not applicable, RV = right ventricular, SD = standard deviation, VV-ECMO = venovenous
extracorporeal membrane oxygenation.
*Unless stated otherwise.
†Results reflect echocardiography done during hospitalization.
‡Defined by criteria of the Acute Kidney Injury Network.10

respiratory infection and 1 (1.0%) patient had non-Candida fungal
respiratory infection. Eight (8.0%) patients had at least 1 positive
blood culture consistent with non-contaminant bacteremia, and 1
(1.0%) patient had Clostridioides difficile infection (Table 4).

Characteristics of patients transferred to ICU after
hospital admission
Twelve of 100 patients (12.0%) were initially admitted to the
ward but were subsequently transferred to ICU because of
CMAJ OPEN, 10(3)
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clinical decompensation shortly after hospitalization (median
0.5, IQR 0–2, d). Compared with patients who remained in a
non-ICU location (n = 68), patients transferred to ICU were
younger (median 63, IQR 53.75–68, yr v. median 76, IQR 60.3–
84.8, yr; p = 0.01). Patients initially admitted to a non-ICU location who were later transferred to ICU were more likely to be
febrile (≥ 38°C; 75.0% v. 28.4%; p = 0.003), have a respiratory
rate of 24 breaths/min or greater (72.7% v. 34.3%; p = 0.02),
and have an oxygen saturation level less than 92% (50.0% v.
11.9%; p = 0.02) on triage vital signs at presentation to hospital.

oxygen on presentation to the emergency department (50.0% v.
26.6%; p = 0.02). On hospital admission, nonsurvivors were
more frequently acidemic (pH < 7.35; 34.5% v. 17.8%; p =
0.04) and had a higher white blood cell count (10.6, IQR 7.1–
14.3, ×109/L v. 6.7, IQR 4.8–8.7, ×109/L; p < 0.01), a lower
hemoglobin level (124, IQR 113–135, g/L v. 134, IQR 123.3–
145.8, g/L; p = 0.03) and a higher troponin level (28, IQR 14.5–
75.5, ng/L v. 18, IQR 8.5–29.5, ng/L; p < 0.01).

Patient outcomes

In this prospective case series involving patients hospitalized
with COVID-19, we found a range of pulmonary and extrapulmonary complications in both ICU and non-ICU patients.
They had a high prevalence of neurologic complications,
thrombotic complications, RV dysfunction and persistent cardiopulmonary pathology after hospital discharge.
Although COVID-19 was initially believed to precipitate
isolated respiratory illness, evidence now characterizes it as a
multisystem disease.3 The full spectrum of organ involvement
and the associated outcomes in patients with COVID-19
remain relatively understudied.
In our study, nearly 10% of patients had a neurologic complication, including ischemic stroke and intracranial hemorrhage. Other studies reported the prevalence of ischemic
stroke to be 2%–6%.11,12 One possible explanation for this
phenomenon is that viral infections can result in an inflammatory cascade and endothelial injury that increase the risk of
arterial thrombotic events.13,14 We also identified intracerebral

Patient outcomes and postdischarge imaging results to Dec. 31,
2020, are shown in Table 5. Thirty-four of 100 patients
(34.0%) died in hospital, including 20 of 68 non-ICU patients
(29.4%) and 14 of 32 ICU patients (43.8%). Persistent abnormalities were observed in 11 of the 19 patients who had CT of
the thorax after discharge from hospital (median duration
of follow-up 108, IQR 41.75–187.75, d). Similarly, 15 patients
had repeat echocardiography after discharge from hospital
(duration of follow-up 81, IQR 57–181, d), of which 1 had persistent LV dysfunction and 5 had persistent RV dysfunction.

Comparing survivors and nonsurvivors

We compared baseline characteristics of patients who did and
did not survive to hospital discharge. Nonsurvivors were older
(median 80, IQR 71.5–87.5, yr v. 68.5, IQR 54.0–77.3, yr; p <
0.01), more frequently presented with tachycardia (88.9% v.
24.1%; p < 0.01) and more frequently received supplemental

Interpretation

Table 5: Outcomes of patients hospitalized with COVID-19 after hospital discharge
No. (%)
Outcome

All patients
n = 100

Non-ICU patients
n = 68

ICU patients
n = 32

Vital status
28-day mortality

28 (28.0)

15 (22.1)

13 (40.6)

Hospital mortality

34 (34.0)

20 (29.4)

14 (43.8)

2/66 (3.0)

0/48 (0)

2/18 (11.1)

Disposition among survivors
Another acute care facility
Rehabilitation centre

12/66 (18.2)

8/48 (16.7)

4/18 (22.2)

Home

47/66 (71.2)

35/48 (72.9)

12/18 (66.7)

5/66 (7.6)

5/48 (10.4)

0/18 (0)

Long-term care facility
CT thorax findings after hospital discharge
Ground-glass opacities

5/19 (26.3)

3/11 (27.3)

2/8 (25.0)

Emphysematous changes or bronchiectasis

6/19 (31.6)

2/11 (18.2)

4/8 (50.0)

Scarring or fibrosis

5/19 (26.3)

0/11 (0)

5/8 (62.5)

1/15 (6.7)

1/10 (10.0)

0/5 (0)

Reduced RV systolic function

2/15 (13.3)

2/10 (20.0)

0/5 (0)

RV dilatation

5/15 (33.3)

3/10 (30.0)

2/5 (40.0)

Echocardiography findings after hospital discharge
Depressed LVEF (30%–50%)

Note: CT = computed tomography, ICU = intensive care unit, LVEF = left ventricular ejection fraction, RV = right ventricular.
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hemorrhage as a potential sequela of COVID-19, with this
complication developing in 6% of ICU patients in our
cohort.15 Intracerebral hemorrhage is hypothesized to be due
to the binding of SARS-CoV-2 to angiotensin-converting
enzyme 2 receptors on endothelial cells of intracranial blood
vessels, resulting in inflammation and disruption of vasculature integrity.16–18
In our cohort, thrombotic events (ischemic stroke, deep
venous thrombosis and pulmonary embolism) occurred in 6%
of non-ICU patients and 19% of ICU patients. Estimates of
thrombotic events in hospitalized patients with COVID-19
have ranged from 5%19 to as high as 33%.20,21 Several mechanisms, including the complement pathway, neutrophil extracellular traps, inflammatory cytokines and endothelial dysfunction may explain why patients with COVID-19 could be
hypercoagulable.22,23 Given the prevalence of thrombotic
events, there may be value in routine surveillance as part of
clinical care for patients with COVID-19. Although there is
currently no evidence to support the routine use of anticoagulation,24 antiplatelet therapy or systemic therapeutic anticoagulation may hold promise as a treatment for very specific subgroups of patients with COVID-19.25
There is a relative paucity of data describing the incidence
of RV dysfunction in patients with COVID-19, which manifests as pulmonary hypertension, systolic failure or dilatation in
these patients. In one observational study, the prevalence of
pulmonary hypertension was 12% in patients with COVID-19
hospitalized in a non-ICU setting.26 In our study, we found
that 31% of hospitalized patients had evidence of pulmonary
hypertension. Although RV dysfunction has been described in
patients with acute respiratory distress syndrome (ARDS), the
prevalence of RV dysfunction in our study is higher than what
has been reported in non-COVID-19 patients with ARDS.27–29
It is possible that RV dysfunction associated with COVID-19
may be pathologically distinct for several reasons. First, macroand microvascular thrombosis from deranged coagulation
pathways could induce RV dysfunction. Second, “permissive
hypoxia” as a treatment strategy may increase the prevalence of
RV dysfunction.30,31
Similarly, we found evidence for long-term pulmonary
complications associated with COVID-19 beyond hospital
discharge. Abnormalities such as bronchiectasis, fibrosis or
scarring were found in 57% of patients who underwent CT of
the thorax after hospital discharge for clinical reasons in our
cohort. Although pulmonary fibrosis in patients recovering
from COVID-19 has been reported in several small cohorts,32
our study reinforces the notion that respiratory dysfunction
can be prevalent and persistent.
These findings highlight the need to elucidate the true
prevalence and potential mechanisms of extrapulmonary
complications associated with COVID-19, particularly
neurologic, thrombotic and cardiac manifestations.
Although, at present, societal guidelines do not recommend the routine use of full-dose anticoagulation for
patients with COVID-19, emerging clinical trial data suggest that systemic therapeutic anticoagulation may hold
promise in improving outcomes among high-risk patients

with COVID-19.33 Future studies should work to identify
the patient phenotype for which the benefits of anticoagulation will outweigh the risks. The prevalence of acute and
long-term RV dysfunction highlights the need to balance
the respiratory support from positive pressure ventilation
with the adverse mechanical effects it frequently imposes
on RV function. Lastly, whereas the acute inpatient management of COVID-19 has garnered attention among the
scientific community, future research should prioritize
characterization of the long-term pulmonary and extrapulmonary complications of COVID-19.
This study has several strengths. We included a cohort of
ICU and non-ICU patients across a spectrum of disease
severity. Standardized diagnostic microbiologic methods were
used to define SARS-CoV-2 positivity. Consecutive prospective enrolment reduced selection bias and improved the fidelity of data collection. We also present granular data on the
pulmonary and extrapulmonary manifestations of COVID-19
and secondary infections among patients with COVID-19 in a
health care setting. We provide data on the clinical outcomes
of patients after hospital discharge. Finally, this study also
provides a detailed experience of patients hospitalized with
COVID-19 starting from hospital admission to beyond hospital discharge.

Limitations

Limitations of any observational study such as this one include
the inability to draw conclusions about causality of any specific
exposure (e.g., therapy or management strategy) with outcomes.
In this study, several diagnostic tests (e.g., ultrasound studies,
CT scans, echocardiograms) were performed on a subgroup of
patients who may have differed from those not assessed owing
to testing and treatment by indication. Furthermore, our cohort
reflects patients at 2 Ontario hospitals during the first wave of
the COVID-19 pandemic. Larger, multicentre cohort studies
are required to provide data that are generalizable beyond the
location of this study and the first wave of the pandemic.

Conclusion

This study provides further evidence that COVID-19 is a
multisystem disease that results in neurologic, cardiac and
thrombotic complications in the acute phase, as well as pulmonary complications that persist beyond the hospitalization. These findings underscore the need to prioritize
research on the long-term outcomes and management of
COVID-19 survivors.
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